Nigeria

in page functions
[French]
Nigeria
Total population (2017) 191,835,907
Birth cohort (2017) 7,322,279
Surviving Infants (surviving to 1 year per year, 2017) 6,822,481
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 69/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 109/1000
World Bank Index, IDA (2015) 3.41
Gross Nation Income (per capita US$, 2015) 2,820
Co-financing group (2018) Accelerated transition
No. of districts/territories (2016) 774

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Nigeria

Type of support

Approvals

2001-2022 (US$)
(28 Mar 2018)

Commitments

2001-2022 (US$)
(28 Mar 2018)

Disbursements

2000-2018 (US$)
(28 Mar 2018)

% Disbursed

(28 Mar 2018)
2001 2002 2003 2004 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Total $791,762,468 $926,595,468 $765,373,706
Health system strengthening (HSS 1) $37,951,144 $37,951,144 $34,072,326 90%
Immunisation services support (ISS) $47,324,000 $47,324,000 $45,704,194 97%
Injection Safety Devices (NVS) $4,067,500 $5,176,500 $5,196,707 128%
Injection safety support (INS) $12,630,270 $12,630,270 $12,610,218 100%
IPV (NVS) $35,541,592 $35,541,592 $30,931,755 87%
Measles SIA (NVS) $22,491,870 $22,491,870 $22,604,288 100%
Measles SIA - Operational costs (OPC) $37,207,046 $37,207,046 $37,207,046 100%
Measles-Follow-up campaign (NVS) $11,209,500 $11,209,500 $11,481,726 102%
Measles-Follow-up campaign op.costs (OPC) $15,703,035 $15,703,035 $14,955,271 95%
Meningitis A (NVS) $4,863,000 $14,040,500
Meningitis A - campaign (NVS) $55,966,777 $55,966,777 $56,057,711 100%
Meningitis A - operational costs (OPC) $43,505,648 $43,505,648 $43,505,648 100%
Penta (NVS) $146,610,194 $153,921,694 $144,669,194 99%
Pneumo (NVS) $210,616,642 $277,063,642 $208,336,446 99%
Rotavirus (NVS) $50,788,000 N/A
Vaccine Introduction Grant (VIG) $15,861,921 $15,861,921 $14,176,839 89%
Yellow Fever (NVS) $39,012,946 $39,012,946 $39,711,793 102%
Yellow Fever - campaign (NVS) $32,627,883 $32,627,883 $34,808,493 107%
YF - Operational costs (OPC) $18,571,500 $18,571,500 $9,344,051 50%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Nigeria DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 45%
M:F sex ratio at birth (2017) 1.06
Household survey: DTP3 coverage for male (2012) 39.40%
Household survey: DTP3 coverage for female (2012) 37.00%
Household survey: Last DTP3 survey (2012) 38%
% districts achieving > 80% DTP3 coverage (2016) 69%
% districts achieving < 50% DTP3 coverage (2016) 6%
MCV WHO/UNICEF estimates (2016) 51%

Breakdown of support

Non-vaccine support Vaccine support
28% 72%
$211,575,593 $553,798,113

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Nigeria

21 December 2017

2017 letter

2017: responding to global challenges

Letter from Gavi's CEO, Dr Seth Berkley.

30 November 2017

Gavi Board Dec 2017 - Nasala village visit

Millions of children set to be protected against typhoid fever

Gavi Board approves US$ 85 million funding window for 2019-2020 to support the introduction of typhoid conjugate vaccine in developing countries.

21 November 2017

Gavi Board meeting, 29-30 November 2017

The Gavi Board meeting was held in Vientiane, Lao PDR on 29-30 November 2017 .

close icon

modal window here